Comparative Pharmacology
Head-to-head clinical analysis: POLARAMINE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLARAMINE versus XYZAL.
POLARAMINE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine
Antihistamine